Home Study Webcast
1.5 Contact Hour(s)
Monday, December 31, 2018
Monday, July 15, 2019
ACPE Expiration Date
Friday, July 16, 2021
Since these drugs inhibit normal checkpoints the problem is they may allow T cells to now recognize normal cells as being foreign, which can lead to serious side effects commonly behaving as autoimmune disease.The newest agents in the immunology-oncology field are Chimeric Antigen Receptor T cells, in which the patients own T cells are genetically modified to produce a receptor for a target on the T cell. Currently approved agents express CD19 and are approved for relapsed/refractory ALL and DLBCL. These are extremely exciting agents which may have the potential for long term remission of cancer. One problem is if the T cells expand too rapidly they release cytokines, called “Cytokine Storm” which can be life threatening. Thus it is critical pharmacists have a good understanding of the mechanisms and adverse events associated with all of these therapies and a good understanding of how to manage the side effects.
PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
PharmCon is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.
In order to obtain a Statement of Credit, participants must score no less than a 70% on the activity's test and complete a program evaluation.
Assistant Professor, University of Michigan College of Pharmacy
This continuing education activity is held as copyright by PharmCon, Inc. Through this notice, PharmCon, Inc. grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).